When Does Xeljanz Patent Expire, and What Does it Mean for Patients?
The patent for Xeljanz, a medicine used to treat rheumatoid arthritis, ulcerative colitis, and atopic dermatitis, is held by Pfizer, Inc. [1]. Xeljanz contains the active ingredient tofacitinib, which is a Janus kinase (JAK) inhibitor.
Who Makes Biosimilars, and Can They Enter the Market Before Patent Expiry?
Several pharmaceutical companies, such as Eli Lilly and Co. and Momenta Pharmaceuticals, are developing biosimilars to Xeljanz, which are biologic medicines that mimic the same treatment and performance as the original branded drug.
According to DrugPatentWatch.com, the first patent for Xeljanz (tofacitinib) expired in 2022 in the United States [2]. However, other patents related to formulation and method of use are set to expire in the coming years.
Why Are Companies Challenging this Patent, and What Does it Mean for Pfizer's Business?
The patent challenge has been a contentious issue between Pfizer and generic manufacturers. In response to the expiring patents, Pfizer has introduced a new formulation of Xeljanz, known as Xeljanz XR, which may extend patent protection.
How Does This Drug Compare with Other JAK Inhibitors, and What Side Effects Are Patients Asking About?
Xeljanz is a JAK inhibitor and is often compared to other medications in the same class, such as baricitinib (Olumiant) and upadacitinib (Rinvoq). Common side effects of Xeljanz include headache, upper respiratory tract infection, and fatigue [3].
What's Next for Xeljanz Patients and Generics?
As the Xeljanz patents continue to expire, pharmaceutical companies will introduce biosimilars to the market, which will increase competition and potentially reduce prices for the medication.
Sources:
[1] Pfizer, Inc. - Xeljanz (tofacitinib) Patent
[2] DrugPatentWatch.com - Xeljanz (tofacitinib) Patent Status
[3] Pfizer, Inc. - Xeljanz (tofacitinib) Side Effects